ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
4 hedge funds and large institutions have $1.2M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2015 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
3,400% more call options, than puts
Call options by funds: $630K | Put options by funds: $18K
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
15% less capital invested
Capital invested by funds: $1.41M → $1.2M (-$208K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$461K |
| 2 |
Jane Street
New York
|
+$393K |
| 3 |
Morgan Stanley
New York
|
+$33.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$1.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $521K | +$393K | +7,994 | +170% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $394K | +$461K | +9,376 | +3,973% |
|
|
CG
3
Cutler Group
San Francisco,
California
| $258K | +$310K | +6,300 | New |
|
|
4
Morgan Stanley
New York
| $28K | +$33.9K | +689 | New |
|
|
VF
5
Virtu Financial
New York
| – | -$1.08M | -16,532 | Closed |
|
ZBIO Hedge Fund Activity: Q4 2015 in Review
4 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q4 2015, worth a combined $1.2M — down 15% from $1.41M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ZBIO positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $461K. The largest seller was Virtu Financial, exiting entirely with an estimated $1.08M sold.
- 4 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q4 2015, up from 3 in Q3 2015.
- Funds reported $1.2M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q4 2015, down 15% quarter-over-quarter.
- 2 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q4 2015 and 1 closed out, a net change of +1 holder.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q4 2015 was Tower Research Capital (TRC), an estimated $461K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q4 2015 was Virtu Financial, an estimated $1.08M sold.
Based on aggregated 13F filings for Q4 2015.